C-YRNHomega-3 epoxyeicosanoid analogs, mitochondrial protection, anti-inflammatory small molecules
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Omeicos Therapeutics omega-3 epoxyeicosanoid analogs, mitochondrial protection, anti-inflammatory small molecules
Omeicos Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class small molecules that target cell-protective pathways. Its lead compound OMT-28 is an orally available synthetic analog of the omega-3 fatty acid metabolite 17,18-EEQ and has been evaluated in Phase 2 studies. The company focuses on mitochondrial dysfunction, inflammatory and cardiovascular diseases, with additional exploratory work in ophthalmology.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Omeicos Therapeutics — Translational · Lower middle. Derived deterministically from 8 extracted project(s). Most-advanced status: phase 2. Band: translational. Modifiers: +5 depth (2 programs at…
Source: Deterministic